These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25234810)

  • 21. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
    Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
    J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
    Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
    Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
    Sofia MJ; Chang W; Furman PA; Mosley RT; Ross BS
    J Med Chem; 2012 Mar; 55(6):2481-531. PubMed ID: 22185586
    [No Abstract]   [Full Text] [Related]  

  • 24. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
    Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
    Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oleanolic acid and ursolic acid: novel hepatitis C virus antivirals that inhibit NS5B activity.
    Kong L; Li S; Liao Q; Zhang Y; Sun R; Zhu X; Zhang Q; Wang J; Wu X; Fang X; Zhu Y
    Antiviral Res; 2013 Apr; 98(1):44-53. PubMed ID: 23422646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.
    Franco S; Casadellà M; Noguera-Julian M; Clotet B; Tural C; Paredes R; Martinez MA
    J Clin Virol; 2013 Dec; 58(4):726-9. PubMed ID: 24140031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Wu JZ; Yao N; Walker M; Hong Z
    Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase.
    Huang JT; Tseng CP; Liao MH; Lu SC; Yeh WZ; Sakamoto N; Chen CM; Cheng JC
    J Virol; 2013 May; 87(9):4994-5004. PubMed ID: 23427160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study.
    Rehman S; Ijaz B; Fatima N; Muhammad SA; Riazuddin S
    Biomed Pharmacother; 2016 Oct; 83():881-891. PubMed ID: 27513212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
    Sims KD; Lemm J; Eley T; Liu M; Berglind A; Sherman D; Lawitz E; Vutikullird AB; Tebas P; Gao M; Pasquinelli C; Grasela DM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3496-503. PubMed ID: 24733462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.